TD Cowen initiated coverage on Aurora Cannabis
$ACB
Medicinal Chemicals and Botanical Products
Health Care
TD Cowen initiated coverage of Aurora Cannabis with a rating of Buy
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/11/2024 | Buy | TD Cowen | |
| 2/9/2024 | Hold → Buy | Canaccord Genuity | |
| 9/21/2022 | Sell → Hold | Canaccord Genuity | |
| 6/24/2022 | Neutral → Overweight | Cantor Fitzgerald | |
| 6/6/2022 | Sell → Hold | Stifel | |
| 11/10/2021 | $9.60 → $10.75 | Neutral | Cantor Fitzgerald |
| 10/28/2021 | $9.50 → $9.60 | Neutral | Cantor Fitzgerald |
| 10/5/2021 | $8.30 → $9.50 | Neutral | Cantor Fitzgerald |
NASDAQ | TSX: ACB Reports Total Net Revenue1 of $88.2 Million, up 37% YoY, Including Record Net Revenue1 of $68.1 Million in Global Medical Cannabis, up 51% YoYGenerates Record Net Income of $31.2 Million, up 282% YoY, and Record Adjusted EBITDA1 of $23.1 Million, up 316% YoYAchieves Target of Positive Free Cash Flow1 in Q3, Generating $27.4 Million of Free Cash Flow1Maintains Strong Balance Sheet with $180 Million of Cash and Debt-Free Cannabis Business2EDMONTON, AB, Feb. 5, 2025 /PRNewswire/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ:ACB) (TSX:ACB), a leading Canada-based global medical cannabis company, today announced its financial and operational results for the third qu
NASDAQ | TSX: ACB EDMONTON, AB, Jan. 22, 2025 /PRNewswire/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ:ACB) (TSX:ACB), the Canadian based leading global medical cannabis company, announced today that it has scheduled a conference call to discuss the results for its third quarter 2025 on Wednesday, February 5, 2025 at 8:00 a.m. Eastern Time | 6:00 a.m. Mountain Time. The Company will report its financial results for the third quarter 2025 before the opening of markets that same day. Conference Call Details DATE: Wednesday, February 5, 2025 TIME: 8:00 a.m. Eastern Time | 6:00 a.m. Mountain Time WEBCAST: Click Here Miguel Martin, Executive Chairman and Chief Executive Officer,
NASDAQ | TSX: ACB Record Adjusted EBITDA1 of $10.1 Million, a YoY increase of 210%Quarterly Net Revenue1 up 29% YoY to $81.1 Million, with 41% growth in Global Medical CannabisRe-Affirms Target of Positive Free Cash Flow1 in the Quarter Ending December 31, 2024Maintains Strong Balance Sheet with ~$152 Million of Cash and a Debt-Free Cannabis Business2EDMONTON, AB, Nov. 6, 2024 /PRNewswire/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ:ACB) (TSX:ACB), a leading Canada-based global medical cannabis company, today announced its financial and operational results for the second quarter fiscal 2025.
Canada's Largest Medical Cannabis Company is an Honouree in The Globe and Mail's 2025 Report on Business Magazine's sixth annual Women Lead Here List EDMONTON, AB, March 31, 2025 /PRNewswire/ - Aurora Cannabis Inc. (NASDAQ:ACB) (TSX:ACB), the Canadian-based leading global medical cannabis company, has been named an honouree on the Globe & Mail's 2025 Report on Business, Women Lead Here list. This annual editorial benchmark recognizes the top publicly traded Canadian companies with the highest gender diversity at the executive level. "As a company with a leading purpose of bein
NASDAQ | TSX: ACB Canada's Largest Medical Cannabis Company to Participate as an Industry Leader in the Inaugural Regulatory Event in Washington, D.C. EDMONTON, AB, March 25, 2025 /PRNewswire/ - Aurora Cannabis Inc. (NASDAQ:ACB) (TSX:ACB), the Canadian-based leading global medical cannabis company, is pleased to be attending, sponsoring and speaking at the 2025 Global Cannabis Regulatory Summit (GCRS), held within the U.S. Capitol Complex in Washington, D.C. on March 26-27, 2025. "The opportunity to speak on this global stage, underscores our position as industry leaders and d
NASDAQ | TSX: ACB Groundbreaking research at Aurora Coast, Aurora's world-class research and development facility, sets new standard in cannabis science EDMONTON, AB, March 20, 2025 /PRNewswire/ - Aurora Cannabis Inc. (NASDAQ:ACB) (TSX:ACB), the Canadian-based leading global medical cannabis company, is pleased to announce the Company's discovery of a novel source of genetic resistance against powdery mildew, PM2, that provides strong protection against this pathogen in cannabis sativa. The development of this proprietary genetic marker technology, which is now in use in Aurora's breeding program, is set to produce powdery mildew resistant cultivars that will be explored for commercial launc
TD Cowen initiated coverage of Aurora Cannabis with a rating of Buy
Canaccord Genuity upgraded Aurora Cannabis from Hold to Buy
Canaccord Genuity upgraded Aurora Cannabis from Sell to Hold
SC 13G/A - AURORA CANNABIS INC (0001683541) (Subject)
SC 13G - AURORA CANNABIS INC (0001683541) (Subject)
SC 13G/A - AURORA CANNABIS INC (0001683541) (Subject)
NASDAQ | TSX: ACB Outgoing Chairman Ron Funk appointed Lead Independent Director, as part of Board leadership transition EDMONTON, AB, Sept. 20, 2024 /PRNewswire/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ:ACB) (TSX:ACB), a leading Canada-based global medical cannabis company, today announced the appointments of CEO Miguel Martin to the additional role of Executive Chairman and outgoing Chairman Ron Funk as Lead Independent Director. Both appointments follow unanimous votes by Aurora's Board and are effective immediately. Mr. Martin has served as Chief Executiv
NASDAQ | TSX: ACB EDMONTON, AB, Aug. 12, 2024 /PRNewswire/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ:ACB) (TSX:ACB), a leading Canada-based global medical cannabis company, is pleased to announce the voting results from its Annual General and Special Meeting of Shareholders (the "Meeting") held Friday August 9, 2024 by virtual webcast. The total number of shares represented by shareholders present in person (virtually) and by proxy at the Meeting was 14,855,306, representing 27.23% of Aurora's issued and outstanding common shares as of the record date. All of
NASDAQ | TSX: ACB Newly created directorship to be filled by Rajesh Uttamchandani EDMONTON, AB, May 15, 2024 /PRNewswire/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ:ACB) (TSX:ACB), the Canadian based leading global medical cannabis company, announced today the appointment of Rajesh Uttamchandani to the Company's Board of Directors (the "Board"), effective today. Mr. Uttamchandani joins the Board with notable expertise in strategy development, innovation, human capital and governance. His impressive career is characterized by executive level roles with leadin
6-K - AURORA CANNABIS INC (0001683541) (Filer)
SUPPL - AURORA CANNABIS INC (0001683541) (Filer)
F-X - AURORA CANNABIS INC (0001683541) (Subject)